
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is expected to experience significant growth potential in the future due to the commercialization of its three products, Afrezza, Furoscix, and V-Go. The company also has multiple near-term catalysts, including the May 29 Afrezza pediatric approval and the FDA approval for the Furoscix ReadyFlow autoinjector on July 26, 2026. With a strong balance sheet and potential for increased sales and partnerships, the company's stock outlook appears promising.
Bears say
MannKind is facing significant risks to achieving its current price target due to potential commercial execution challenges, clinical trial setbacks, regulatory hurdles, and dependence on a larger partner for the commercialization of its key products. The company has also announced a potential second product in collaboration with United Therapeutics, which could provide significant revenue upside, but this is a long-term opportunity that may face delays and uncertainties. The current valuation is based on optimistic future revenue expectations, and any setbacks could impact the company's stock performance.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares